Cytokine profiling for prediction of symptomatic radiation-induced lung injury

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 5, 2005, Pages 1448-1454

  Hart, Justin P ^a   Broadwater, Gloria ^a   Rabbani, Zahid ^a   Moeller, Benjamin J ^a   Clough, Robert ^a   Huang, Dale ^a   Sempowski, Gregory A ^a   Dewhirst, Mark ^a   Pizzo, Salvatore V ^a   Vujaskovic, Zeljko ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokines; Interleukin 8; Symptomatic radiation induced lung injury; Transforming growth factor 1

Indexed keywords

ONCOLOGY; PATIENT MONITORING; PROTEINS; TOXICITY; TUMORS;

CYTOKINES; INTERLEUKIN-8; SYMPTOMATIC RADIATION-INDUCED LUNG INJURY; TRANSFORMING GROWTH FACTOR Β1;

RADIOTHERAPY;

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DEVICE; DISEASE MARKER; FEMALE; HUMAN; IMMUNOCHEMISTRY; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; RADIATION INJURY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYMPTOM;

AGED; BIOLOGICAL MARKERS; CYTOKINES; ENDPOINT DETERMINATION; FEMALE; HUMANS; INTERLEUKIN-8; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744431877     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.05.032     Document Type: Article

References (45)

1. G.H. Fletcher Clinical dose-response curves of human malignant epithelial tumours Br J Radiol 46 1973 1 12
2. X.L. Fu, G.L. Jiang, L.J. Wang Hyperfractionated accelerated radiation therapy for non-small cell lung cancer Clinical phase I/II trial Int J Radiat Oncol Biol Phys 39 1997 545 552
3. S.C. King, J.C. Acker, P.S. Kussin High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer Unusual toxicity and promising early results Int J Radiat Oncol Biol Phys 36 1996 593 599
4. A.T. Turrisi 3rd, K. Kim, R. Blum Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 340 1999 265 271
5. M.S. Anscher, L.B. Marks, T.D. Shafman Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy Int J Radiat Oncol Biol Phys 56 2003 988 995
6. L.B. Marks, J. Garst, M.A. Socinski Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium J Clin Oncol 22 2004 4329 4340
7. Y. Chen, P. Rubin, J. Williams Circulating IL-6 as a predictor of radiation pneumonitis Int J Radiat Oncol Biol Phys 49 2001 641 648
8. C.J. Johnston, J.P. Williams, A. Elder Inflammatory cell recruitment following thoracic irradiation Exp Lung Res 30 2004 369 382
9. American Joint Committee on Cancer manual for staging of cancer Lung cancer I.D. Fleming J.S. Cooper D.E. Henson 5th ed. 1997 Lippincott-Raven Philadelphia 127 137
10. M.S. Anscher, T. Murase, D.M. Prescott Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis Int J Radiat Oncol Biol Phys 30 1994 671 676
11. F.M. Kong, M. Anscher, R.L. Jirtle Tumor marker protocols Plasma transforming growth factor beta, a plasma tumor marker M. Hannausek Z. Walazek Methods in molecular medicine 1998 Humana Press Totowa, NJ 417 430
12. X.L. Fu, H. Huang, G. Bentel Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta Int J Radiat Oncol Biol Phys 50 2001 899 908
13. M.S. Anscher, W.P. Peters, H. Reisenbichler Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer N Engl J Med 328 1993 1592 1598
14. M.S. Anscher, F.M. Kong, L.B. Marks Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis Int J Radiat Oncol Biol Phys 37 1997 253 258
15. F.M. Kong, M.S. Anscher, T. Murase Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor Ann Surg 222 1995 155 162
16. Z. Vujaskovic, Q.F. Feng, Z.N. Rabbani Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity Exp Lung Res 28 2002 577 590
17. Z. Vujaskovic, I. Batinic-Haberle, Z.N. Rabbani A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury Free Radic Biol Med 33 2002 857 863
18. Z. Vujaskovic, Q.F. Feng, Z.N. Rabbani Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity Radiat Res 157 2002 656 660
19. M.S. Anscher, F.M. Kong, K. Andrews Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis Int J Radiat Oncol Biol Phys 41 1998 1029 1035
20. Lowry R. Clinical calculator 2: Predictive values and likelihood ratios. Available at: http://faculty.vassar.edu/lowry/clin2.html. Accessed on May 21, 2004.
21. M.K. Martel, R.K. Ten Haken, M.B. Hazuka Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis Int J Radiat Oncol Biol Phys 28 1994 575 581
22. M. Roach 3rd, D.R. Gandara, H.S. Yuo Radiation pneumonitis following combined modality therapy for lung cancer Analysis of prognostic factors J Clin Oncol 13 1995 2606 2612
23. T.I. Lingos, A. Recht, F. Vicini Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy Int J Radiat Oncol Biol Phys 21 1991 355 360
24. R.I. Rothwell, S.A. Kelly, C.A. Joslin Radiation pneumonitis in patients treated for breast cancer Radiother Oncol 4 1985 9 14
25. R.P. Abratt, G.W. Morgan Lung toxicity following chest irradiation in patients with lung cancer Lung Cancer 35 2002 103 109
26. Z. Vujaskovic, L.B. Marks, M.S. Anscher The physical parameters and molecular events associated with radiation-induced lung toxicity Semin Radiat Oncol 10 2000 296 307
27. N. Barthelemy-Brichant, L. Bosquee, D. Cataldo Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy Int J Radiat Oncol Biol Phys 58 2004 758 767
28. Y. Chen, J. Williams, I. Ding Radiation pneumonitis and early circulatory cytokine markers Semin Radiat Oncol 12 2002 26 33
29. C. Linard, C. Marquette, J. Mathieu Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat Effect of an NF-kappaB inhibitor Int J Radiat Oncol Biol Phys 58 2004 427 434
30. M. Orditura, F. De Vita, G. Catalano Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients Relationship with prognosis J Interferon Cytokine Res 22 2002 1129 1135
31. J.J. Chen, P.L. Yao, A. Yuan Up-regulation of tumor interleukin-8 expression by infiltrating macrophages Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clin Cancer Res 9 2003 729 737
32. K. Matsushima, C.G. Larsen, G.C. DuBois Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line J Exp Med 169 1989 1485 1490
33. T. Yoshimura, E.A. Robinson, E. Appella Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence Mol Immunol 26 1989 87 93
34. M. Baggiolini, B. Dewald, B. Moser Human chemokines An update Annu Rev Immunol 15 1997 675 705
35. A.D. Luster Chemokines - chemotactic cytokines that mediate inflammation N Engl J Med 338 1998 436 445
36. N. Mukaida Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases Am J Physiol Lung Cell Mol Physiol 284 2003 L566 L577
37. J. Heidemann, H. Ogawa, M.B. Dwinell Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2 J Biol Chem 278 2003 8508 8515
38. A. Li, S. Dubey, M.L. Varney IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis J Immunol 170 2003 3369 3376
39. J.R. Dunlevy, J.R. Couchman Interleukin-8 induces motile behavior and loss of focal adhesions in primary fibroblasts J Cell Sci 108 Pt. 1 1995 311 321
40. W.S. Simonet, T.M. Hughes, H.Q. Nguyen Long-term impaired neutrophil migration in mice overexpressing human interleukin-8 J Clin Invest 94 1994 1310 1319
41. U.H. von Andrian, J.D. Chambers, L.M. McEvoy Two-step model of leukocyte-endothelial cell interaction in inflammation Distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo Proc Natl Acad Sci U S A 88 1991 7538 7542
42. M.W. Epperly, H. Guo, D. Shields Correlation of ionizing irradiation-induced late pulmonary fibrosis with long-term bone marrow culture fibroblast progenitor cell biology in mice homozygous deletion recombinant negative for endothelial cell adhesion molecules In Vivo 18 2004 1 14
43. D. Masuya, C. Huang, D. Liu The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients Cancer 92 2001 2628 2638
44. A. Yuan, P.C. Yang, C.J. Yu Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer Am J Respir Crit Care Med 162 2000 1957 1963
45. American Urological Association Prostate-specific antigen (PSA) best practice policy Oncology (Huntingt) 14 2000 267 272 277-268, 280 passim